GlassScriptPhysician profile
Shana O Hackworth
NPI 1710029277
$7,685.78
in general payments reported to CMS, 2019-2025
25 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $1,203 · 2023: $1,482 · 2024: $2,177 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,233.58 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,527.39 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,340.99 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $1,339.61 | 2021-2025 | |
| Janssen Biotech, INC. | $688.69 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $537.60 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $240.85 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Arcutis Biotherapeutics, INC. | $236.19 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $209.53 | 2022-2024 | Vtama |
| Leo Pharma INC. | $208.14 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $185.51 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Vyne Pharmaceuticals INC. | $178.60 | 2021 | |
| Ucb, INC. | $156.54 | 2021-2025 | Bimzelx, Cimzia |
| Botanix Sb INC | $139.79 | 2025 | Sofdra |
| Pfizer INC. | $112.11 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.96 | 2021-2025 | Jublia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $92.97 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $84.05 | 2024-2025 | |
| Amgen INC. | $73.12 | 2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.64 | 2022-2025 | Spevigo |
| Lilly USA, LLC | $49.70 | 2021 | |
| Organon LLC | $37.85 | 2025 | Vtama |
| Biofrontera INC. | $27.07 | 2021 | |
| Dermira, INC. | $19.80 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.57 | 2024 | Nuzyra |
| Kyowa Kirin, INC. | $15.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shana Hackworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.